Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19149608 | 0.88 | HDAC6 (0.36) | AAK1MMP13CHRNB2CHRNA4HDAC6 | |
| SCHEMBL6418739 | 0.86 | HDAC6 (0.38) | AAK1MMP13CHRNB2CHRNA4HDAC6 | |
| SCHEMBL6418732 | 0.86 | HDAC6 (0.38) | AAK1MMP13CHRNB2CHRNA4HDAC6 | |
| SCHEMBL18352602 | 0.83 | HDAC6 (0.35) | AAK1CHRNB2CHRNA4HDAC6HDAC1 | |
| SCHEMBL18352511 | 0.83 | HDAC6 (0.35) | AAK1CHRNB2CHRNA4HDAC6HDAC1 | |
| SCHEMBL8248471 | 0.82 | AAK1 (0.34) | AAK1MMP13CHRNB2CHRNA4HDAC6 | |
| SCHEMBL16751215 | 0.82 | AAK1 (0.34) | AAK1MMP13CHRNB2CHRNA4HDAC6 | |
| SCHEMBL16812760 | 0.79 | ADRB2 (0.50) | MMP13 | |
| SCHEMBL7351512 | 0.79 | AAK1 (0.34) | AAK1MMP13CHRNB2CHRNA4HDAC6 | |
| SCHEMBL10473406 | 0.79 | AAK1 (0.34) | AAK1MMP13CHRNB2CHRNA4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031613-A1 | COMPOUNDS AND METHODS FOR THEIR USE IN THE TREATMENT OF MALARIA | UNIVERSITY OF SOUTH FLORIDA | 2019-01-31 | — | — | US | disclosed |
| WO-2017127820-A1 | COMPOUNDS AND METHODS FOR THEIR USE IN THE TREATMENT OF MALARIA | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031613-A1 | COMPOUNDS AND METHODS FOR THEIR USE IN THE TREATMENT OF MALARIA | G6PD, DHFR, GLS2 | AAK1 4410/4885MMP13 2974/4885CHRNB2 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.